The Kentucky Neuroscience Institute (KNI) integrates the expertise of the University of Kentucky’s
neurosurgery physicians and researchers. KNI is a regional referral center dedicated to providing comprehensive care to our patients. Physicians and scientists from both disciplines work collaboratively to find the causes and design new treatments for neurological disorders.
Neurosurgeons and neurologists at KNI provide diagnosis and management of a wide spectrum of neurological conditions involving the brain, spine and nervous system. We are comprised of a highly experienced team of physicians that can treat children
and adults. Our team of world-renowned clinicians uses the most advanced surgical and medical treatments for brain diseases and disorders. UK is on the leading edge of patient care and is taking the next step by putting the power of an entire team of
specialists to work on your condition.
UK is first in the U.S. to conduct trial of new Parkinson’s disease treatment. A clinical trial being conducted at UK is investigating a new treatment strategy for Parkinson’s disease that, if successful, could drastically change future treatment of the disease and possibly halt or reverse brain degeneration. UK is the first in the U.S. to conduct the clinical trial.
Craig van Horne, MD, associate professor of neurosurgery in the College of Medicine and principal investigator of the clinical trial, came to the Kentucky Neuroscience Institute only two years ago, but he is already making significant contributions to research and patient care related to Parkinson’s disease. If successful, this procedure could significantly change the treatment of Parkinson’s disease and could have an impact on other neurodegenerative disorders as well. Learn more.
UK HealthCare's Stroke Program has received the American Heart Association/American Stroke Association’s Get With The Guidelines®-Stroke Gold Plus Quality Achievement Award. The award recognizes the program’s commitment and success in implementing excellent care for stroke patients, according to evidence-based guidelines. Read more about the Gold Plus Award »
Stroke patients at the Kentucky Neuroscience Institute have access not only to the region's top doctors, but also to the most advanced medical technology. The stroke center at UK Chandler Hospital was the first in the region to be designated as a Comprehensive Stroke Center.
LEXINGTON, Ky. (Nov. 30, 2015) — Dozens of neurologists, other medical professionals and researchers gathered at the University of Kentucky Nov. 25 to hear the words of Dr. Walter Koroshetz, director of the National Institute of Neurological Disease and Stroke of the National Institutes of Health.
In his first year as director, Koroshetz has made it a point to travel around the U.S. to share the Institute's plans to reduce the burden of neurological disease through vigorous investments in basic, translational and clinical research.
Alzheimer's disease, Parkinson's disease or multiple sclerosis are the most commonly known neurological diseases. However, Koroshetz reminded the audience that this classification includes disorders like substance abuse, depression and neurodevelopmental diseases.
"Neurological disease is today what infectious disease was to the 20th century: the most disabling and expensive group of chronic diseases today," Koroshetz said.
The good news: the world has begun to recognize the potential economic and quality-of-life impact of investment in research in the neurosciences. The brain and its mysterious functions — and malfunctions — has caught the eye of major consumer publications like Time, Scientific American, and National Geographic. There are rising numbers of Ph.D. candidates in the neurosciences. And the U.S. Congress has requested that the NIH present directly to them plans (and an accompanying budget) to solve the mysteries of neurological diseases, bypassing the usual funding mechanisms. Previously, only cancer and AIDS have been blessed with this designation.
As a part of that process, several government agencies and private groups have banded together to form The Brain Initiative. Called "The Next Great American Project," the Brain Initiative's goal is to provide the tools and resources necessary to map and understand the circuits and networks in the brain. By doing so, the hope is to understand how brain circuits function, find the basic mechanisms by which cellular pathways contribute to circuit dysfunction, and figure out ways to improve outcomes for patients.
That effort will require a whole new set of tools, says Koroshetz. He points out that while advances in imaging have revolutionized how we look at the brain, we are still largely reliant on antiquated technology.
"The EEG was developed in the 1920's, and the MRI, while effective, only records images at the rate of one per half a second, whereas the brain fires in milliseconds,” Koroshetz explained. "It's said that new tools are often more valuable than new concepts, and that is equally applicable in this case."
Dr. Larry Goldstein, chair of the UK Department of Neurology, emphasized the importance of Koroshetz's message.
"The Brain Initiative is the Manhattan Project of our age, and pursuit of effective treatments for this group of debilitating and costly diseases is a worthy cause," Goldstein said.
Goldstein added that, in light of the fact that UK already has research strengths in several relevant areas such as Alzheimer’s disease and related disorders, epilepsy, stroke, spinal cord and brain injury, Parkinson’s disease, and substance abuse, having Koroshetz present to UK faculty and staff was particularly timely.
"We were extremely fortunate to have Dr. Koroshetz as our guest at UK HealthCare to help welcome the advent of a new chapter in neurological research both at UK and around the world."
LEXINGTON, Ky. (Nov. 14, 2015) —The American Board of Psychiatry and Neurology (ABPN) has named Dr. Jonathan H. Smith of the University of Kentucky a recipient of its Faculty Innovation in Education award to support the development of innovative education projects that provide effective residency and fellowship training, as well as lifelong learning for practicing psychiatrists and neurologists.
Every year up to two neurologists are selected for this prestigious award. The two-year award provides a maximum of $100,000. Smith's project will explore the use of unannounced simulated patients to evaluate neurology residents' communication and interpersonal skills.
Dr. Larry Goldstein, chair of the UK Department of Neurology, said Smith's work reflects the department’s long-term emphasis in providing the best possible experience for trainees. “Jonathan is an excellent teacher with a creative approach to neurology resident education, and this award is a well-deserved acknowledgment of that," said Goldstein.
Smith is currently an assistant professor in Neurology and the program director of adult neurology residency at UK. He is a graduate of the University of Rochester with a B.S. in biochemistry and a minor in clinical psychology. He received his M.D. from the Chicago Medical School at Rosalind Franklin University of Medicine and Science. He completed his neurology residency and headache fellowship at the Mayo Clinic, where he also served as chief resident.
Some of Smith's previous awards include the American Academy of Neurology’s (AAN) Annual Meeting Resident Scholarship Award in 2011 and the Chief Resident Award at the Mayo Clinic Department of Neurology in June 2012, and the Excellence in Teaching in the Department of Neurology award at UK in June 2015.
The ABPN’s main mission is to develop and provide valid and reliable procedures for certification and maintenance of certification in psychiatry and neurology. They have been a non-profit since 1934 and are one of 24 boards of the American Board of Medical Specialties (ABMS).
Media contact: Laura Dawahare, Laura.Dawahare@uky.edu, (859) 257-5307
LEXINGTON, Ky. (Nov. 11, 2015) — Two women, seated at a table, told their stories in quiet tones. A group of chefs, some standing, others seated, leaned forward eagerly, clearly interested in what these two women had to say. They peppered the women with questions: did food taste better cold or hot? Was texture an issue? Did a glass of wine before dinner help or hurt the flavor experience?
The women have both taken chemotherapy for their cancer. One of them — Gina Mullin — will be taking chemotherapy every three weeks for the rest of her life. Both she and patient Jen Cooper tell heartbreaking stories about a side effect of chemotherapy that gets swept under the rug: food tastes terrible.
"Can you imagine how much quality of life you lose when you can't enjoy your food?" asked Cooper.
Chemotherapy, by design, kills all fast-growing cells in the body. As cancer cells die, so do all the healthy fast-growing cells, including the cells responsible for hair growth and taste buds. So your hair falls out and everything tastes metallic.
"Here they are, critically ill, needing good nutrition more than ever and they can't enjoy food? It's beyond unfair," said Dan Han, a neuropsychologist at the University of Kentucky.
Han has become an ardent advocate for the concept that quality of life issues — specifically, the enjoyment of food — should be measured as a clinical outcome for patients. A chance meeting in 2012 with internationally acclaimed chef Fred Morin brought the issue to his attention.
"Like most clinicians, when patients brought up the issue of reduced or distorted flavor perception (if they brought it up at all), I was sympathetic but not motivated, because there's not much we can do to help," said Han.
But Morin, chef and owner of the legendary restaurant Joe Beef, is a bioengineer by training and hugely interested in the concept of neurogastronomy, which merges the science and culinary worlds by studying the human brain and the behavior that influences how we experience food. Morin encouraged Han to read a book by Yale neuroscientist Gordon Shepherd, who coined the term in 2006.
"I was hooked," said Han. "I knew that if we could bring together chefs, neuroscientists and food scientists to explore ways to help these patients enjoy a meal, break bread with family and friends and enjoy that process again, it would be a significant contribution to science and to life."
That chance meeting was the spark for the founding of the International Society of Neurogastronomy (ISN), and last week more than 200 scientists, patients, chefs, foodies and others gathered at UK for the inaugural ISN Symposium, sharing their knowledge and exploring opportunities to improve quality of life for people who have lost their perception of taste or smell due to cancer, brain injury, stroke, Alzheimer's, Parkinson's, or other neurological disorders.
During breaks, participants were encouraged to visit eight tasting stations, where experiments demonstrated how the perception of flavor is shaped by more than just the tongue. Attendees wore blindfolds, sniffed scent jars, held their noses, and more while they sampled. At one station, tasters eating a pink cookie while listening to gentle music were astonished to learn that it was equally as sweet as the black cookie paired with harsh music.
The most emotional part of the day looped back to the conversation between the chefs and the cancer patients. Chefs were paired with neuroscientists and physicians to create two teams, which then competed in the "Applied Neurogastronomy Challenge "— a friendly competition to make food that appealed to Mullin and Cooper.
"Team Morin" prepared a chunky potato soup with a range of toppings to customize the flavor experience: diced potato and bacon, pulled chicken and ginger, garlic broccoli, and fried chicken skin with paprika. "Team Mehta" also took a mix and match approach, offering peppered scallops, grilled chicken and mustard lime halibut to be paired with chili jam, apple goji reduction, lemon marinated apples, carrot yogurt salsa, or a chocolate chili mole.
"I tried every dish, and it was really fun," said Mullin, who said the only time she cried during her diagnosis and treatment was the day she ordered two of her favorite restaurant dishes only to throw them away after one bite because they tasted so bad.
"Potato soup wins!" shouted Jen Cooper to widespread applause. In truth, replied Leah Sarris, program director for the Goldring Center for Culinary Medicine at Tulane University and a member of Team Morin, everyone won.
"I learned so much from you, Jen and Gina, and it will inform the way I cook and teach others to cook," she said. "We read in books about how chemo affects taste, but your stories made it real."
While neurogastronomy, as a science, is still in its infancy, the symposium has opened the door to the flow of information and ideas among neuroscientists, culinary professionals, food scientists and agriculture scientists. Participants were enthusiastic about the day's successes and the prospect for continued conversations that advance the science in the context of neurologically-related taste impairments, sustainability, disease prevention, and more.
"This really organically grew into something amazing, because people from such randomly different disciplines came together," said Han. "The commonality that united us was to achieve better food, better flavor, better health, and better quality of life."
To view the symposium presentations, go to https://vimeo.com/album/3650327
LEXINGTON, Ky. (Oct. 22, 2015) — A new science called neurogastronomy explores brain and behavior in the context of food, and the International Society of Neurogastronomy's inaugural symposium will bring together for the first time the "four pillars" of neurogastronomy to share their knowledge and begin a dialogue that, they hope, will ultimately lead to real changes in brain behavior as it relates to food.
Registration is still open for the symposium, which will take place Saturday, Nov. 7, 2015, in Pavilion A of the Albert B. Chandler Hospital. UK Neuropsychologist Dan Han and his ISN co-founders have structured the day to be very different than the typical scientific symposium. Instead of long lectures, there are several presentations in a TED-talk style format. Among the speakers:
Chefs: Next Iron Chef Runner-up Jehangir Mehta; James Beard finalist and Mind of a Chef host Ed Lee; Leah Sarris, program director for the Goldring Center for Culinary Medicine at Tulane University; and Fred Morin of Joe Beef Montreal.
Scientists: Physiologist Tim McClintock; prize-winning experimental psychologist Charles Spence; and Dr. Gordon Shepherd, who coined the term neurogastronomy -— first in 2006 in an article in Nature and six years later in an eponymous book.
The symposium will be a true culinary experience as well, with tasting breaks to help participants grasp the fundamentals of flavor perception (sweet, salty, umami, etc.) and chef-quality breakfast and lunch breaks.
Han is anxious to begin the dialogue that might ultimately provide tangible improvement to quality of life for people with neurologically-related taste impairments. "When the concept of neurogastronomy was introduced, people realized it was a need that had been there for a long time – ever since mammals started eating," Han said. "If we could get together and simply provide ways to help these patients enjoy a meal, break bread with family and friends and enjoy that process again, then I would be very proud of that contribution to clinical sciences."
For more information about the ISN Symposium or to register, go to http://www.isneurogastronomy.org/
LEXINGTON, Ky. (Oct. 7, 2015) – UK HealthCare has more than 125 physicians practicing medicine with UK Albert B. Chandler Hospital, Kentucky Children's Hospital, UK Good Samaritan Hospital and Shriner's Hospitals for Children who appear on the Best Doctors in America list for 2015-16 – more than any other hospital in Kentucky. Only 5 percent of doctors in America earn this honor, decided by impartial peer review.
The Best Doctors in America list, assembled by Best Doctors Inc. and audited and certified by Gallup, results from polling of more than 40,000 physicians in the United States. Doctors in more than 40 specialties and 400 subspecialties of medicine appear on this year’s List.
The experts who are part of the Best Doctors in America database provide the most advanced medical expertise and knowledge to patients with serious conditions – often saving lives in the process by finding the right diagnosis and right treatment.
2015-16 Best Doctor's List:
Sadiq Ahmed Nephrology
Kenneth B. Ain Endocrinology and Metabolism
Michael I. Anstead Pediatric Specialist
Rony K. Aouad Otolaryngology
Susanne M. Arnold Medical Oncology and Hematology
Henrietta Salvilla Bada Pediatric Specialist
Hubert O. Ballard Pediatric Specialist
Robert J. Baumann Child Neurologist
Louis Bezold Pediatric Specialist
Peter James Blackburn Ophthalmology
Christopher A. Boarman Pediatrics
David C. Booth Cardiovascular Disease
Edwin A. Bowe Anesthesiology
Robert A. Broughton Pediatric Specialist
Raeford E. Brown, Jr. Pediatric Specialist
Scottie B. Day Pediatric Specialist
Christopher P. DeSimone Obstetrics and Gynecology
Philip A. DeSimone Medical Oncology and Hematology
David J. DiSantis Radiology
John Draus Pediatric Specialist
John H. Eichhorn Anesthesiology
Eric D. Endean Vascular Surgery
Deborah R. Erickson Urology
B. Mark Evers Surgery
John L. Fowlkes Pediatric Specialist
Peter J. Giannone, Jr. Pediatric Specialist
Jacqueline S. Gibson Internal Medicine
Larry B. Goldstein Neurology
Donna G. Grigsby Pediatrics
John C. Gurley Cardiovascular Disease
Wendy Fetterman Hansen Obstetrics and Gynecology
Andrew Hoellein Internal Medicine
Robert Hosey Family Medicine
Joseph A. Iocono Pediatric Specialist
Mary Lloyd Ireland Orthopaedic Surgery
Henry Iwinski Pediatric Specialist
Gregory A. Jicha Neurology
Darren Lee Johnson Orthopaedic Surgery
Raleigh O. Jones Otolaryngology
Jamshed F. Kanga Pediatric Specialist
Dennis Karounos Endocrinology and Metabolism
Edward J. Kasarskis Neurology
Douglas G. Katz Ophthalmology
Philip A. Kern Endocrinology and Metabolism
Stefan G. Kiessling Pediatric Specialist
Mahesh R. Kudrimoti Radiation Oncology
Cheri D. Landers Pediatric Specialist
Philip B. Latham Pediatrics
Steve W. Leung Cardiovascular Disease
Robert W. Lightfoot, Jr. Rheumatology
Richard Lock Anesthesiology
Grace F. Maguire Pediatrics
Scott D. Mair Orthopaedic Surgery
Hartmut H. Malluche Nephrology
Jeremiah T. Martin Thoracic Surgery
Erich C. Maul Pediatrics
Hanna W. Mawad Nephrology
Ronald Charles McGarry Radiation Oncology
Patrick C. McGrath Surgical Oncology
Adrian W. Messerli Cardiovascular Disease
Todd Milbrandt Pediatric Specialist
David J. Minion Vascular Surgery
Amr El-Husseini Mohamed Nephrology
David J. Moliterno Cardiovascular Disease
Alba E. Morales Pediatric Specialist
Peter E. Morris Critical Care Medicine
Timothy W. Mullett Thoracic Surgery
Kevin R. Nelson Neurology
Nicholas J. Nickl III Gastroenterology
M. Elizabeth Oates Radiology
John M. O'Brien, Jr. Obstetrics and Gynecology
Hatim A. Omar Pediatric Specialist
Amit Patel Plastic Surgery
Kevin A. Pearce Geriatric Medicine
P. Andrew Pearson Ophthalmology
Luther C. Pettigrew, Jr. Neurology
Barbara A. Phillips Sleep Medicine
Thomas Pittman Pediatric Specialist
Andrew R. Pulito* Pediatric Specialist
Marcus E. Randall Radiation Oncology
Annette Rebel Critical Care Medicine
Hassan K. Reda Thoracic Surgery
Aru Reddy Pediatric Specialist
L. Raymond Reynolds Endocrinology and Metabolism
Julie Ribes Pathology
Scott A. Riley Hand Surgery
John J. Rinehart* Medical Oncology and Hematology
Kimberly Ringley Pediatrics
William C. Robertson, Jr. Child Neurologist
David W. Rudy Clinical Pharmacology, Internal Medicine
Sarah S. Rugg Cardiovascular Disease
Sibu P. Saha Thoracic Surgery
Sheila P. Sanders Ophthalmology
B. Peter Sawaya Nephrology
Douglas J. Schneider Pediatric Specialist
Jeffrey Bryan Selby Orthopaedic Surgery
Lori Shook Pediatric Specialist
Michael Sekela Thoracic Surgery
John Slevin Neurology
David A. Sloan Surgical Oncology
Charles D. Smith, Jr. Neurology
Mikel D. Smith Cardiovascular Disease
Susan Smyth Cardiovascular Disease
Vincent L. Sorrell Cardiovascular Disease
William Henry St. Clair Radiation Oncology
Carol Steltenkamp Pediatrics
Julia C. Stevens Pediatric Specialist
Stephen Strup Urology
Lisa R. Tannock Endocrinology and Metabolism
Vishwas R. Talwalkar Pediatric Specialist
Alice C. Thornton Infectious Disease
Kathryn M. Thrailkill Pediatric Specialist
Phillip A. Tibbs Neurological Surgery
Dale E. Toney Internal Medicine
Fred Rand Ueland Obstetrics and Gynecology
Joseph Valentino Otolaryngology
Craig Van Horne Neurological Surgery
Woodford S. Van Meter Ophthalmology
John R. van Nagell Obstetrics and Gynecology
Henry C. Vasconez Pediatric Specialist, Plastic Surgery
Lars M. Wagner Pediatric Specialist
Carmel Wallace Pediatrics
Gretchen Lois Wells Cardiovascular Disease
Thomas French Whayne, Jr. Cardiovascular Disease
Michael L. Wittkamp Pediatric Specialist
Thomas L. Young Pediatrics
Khaled M. Ziada Cardiovascular Disease
Joseph B. Zwischenberger Critical Care Medicine, Thoracic Surgery
LEXINGTON, Ky. (Sept. 29, 2015) — Register now for the inaugural International Society of Neurogastronomy symposium, which will be held at the University of Kentucky on Nov. 7, 2015. Featuring speakers like "Mind of a Chef" host and restauranteur Ed Lee and the father of neurogastronomy, Dr. Gordon Shepherd, the symposium will explore the concept of brain and behavior in the context of food.
The term, "neurogastonomy, was coined by Dr. Gordon Shepherd, professor of neurobiology at Yale University — first in 2006 in an article in Nature and six years later in an eponymous book. While Shepherd has been interested in the concept from a research perspective, UK neuropsychologist Dan Han and a group of neuroscientists, chefs and food scientists are enthusiastic about making it a clinical translational science, with applications in cancer, stroke and brain injury, (which can destroy the sense of taste) and disease like diabetes and heart disease.
The day's format differs from the typical symposium, featuring brief presentations modeled after the popular TED talks and punctuated with breaks for tastings and a contest where food from regional and national chefs will be judged by patients with taste impairments.
For more information about the symposium and how to register, click here.
LEXINGTON, Ky. (Aug. 4, 2015) -- The inaugural International Society of Neurogastronomy symposium will be held at the University of Kentucky on Nov. 7, 2015. Featuring speakers like Emmy-winning chef Sean Brock and the father of neurogastronomy, Dr. Gordon Shepherd, the symposium will explore the concept of brain and behavior in the context of food.
The term Neurogastonomy was coined by Dr. Gordon Shepherd, professor of neurobiology at Yale University, in 2006 in an article in Nature and six years later in an eponymous book. While Shepherd has been interested in the concept from a research perspective, UK neuropsychologist Dan Han and a group of neuroscientists, chefs and food scientists are enthusiastic about making it a clinical translational science, with applications in cancer, stroke, and brain injury (which can destroy the sense of taste) and disease like diabetes and heart disease.
The day's format differs from the typical symposium, featuring brief presentations modeled after the popular TED talks and punctuated with breaks for tastings and an iron chef-like contest where the food from regional and national chefs will be judged by patients with taste impairments.
Symposium registration opens Aug. 7. For more information about the symposium and how to register, click here.
LEXINGTON, Ky. (June 22, 2015) — There is growing excitement among headache specialists about initial research into a new class of anti-migraine drugs.
Called CGRP monoclonal antibodies, these drugs appear to significantly reduce the frequency of migraine in human clinical trials.
"We know that levels of CGRP are elevated during migraine attacks and decrease with resolution of the attacks," said Sid Kapoor, MD, Fellow of the American Headache Society and Director of the Headache Program at the University of Kentucky's Kentucky Neuroscience Institute (KNI). "This new class of drugs aims to reduce CGRP levels either by inactivating CGRP or disabling the receptor that binds to it, effectively disrupting the chain of events that causes migraine pain."
These drugs have significant potential to change the landscape for migraine treatment, Kapoor said.
"Currently, my only course of action is to patiently and methodically work through a morass of drugs for blood pressure, depression, or epilepsy, and if those don't work, it's on to more complex and expensive therapy options like Botox," Kapoor said. "It's a frustrating process for both the doctor and the patient."
"If these CGRP drugs can deliver as promised, they will represent the first new class of anti-migraine drugs in more than 20 years -- and those only treated migraines after they occurred, and rarely prevented them."
What's particularly exciting to headache specialists is the profound effect the drugs appear to have on migraine incidence. Initial results from Phase II studies on each of the four drugs currently in development reveal huge reductions in the incidence of migraine — one drug, from Alder BioPharmaceuticals, has demonstrated reductions from 50 percent to almost 100 percent.
So why aren't these drugs being rushed to market? Not so fast, Kapoor said.
"We don't yet fully know how blocking CGRP affects other organ functions long term. Previous attempts at modifying this pathway were too dangerous for patients and studies had to be discontinued. It is exciting that we are succeeding with a fresh approach."
CGRP monoclonal antibody drugs are at least five years away from public distribution. The next step is Phase III trials, which aim to establish efficacy and long-term safety compared to a placebo.
"Pain studies are notorious for a high placebo response and hence this step will be critical," Kapoor said.
According to the American Headache Society, more than 36 million Americans suffer from migraine attacks, and about four million of those people experience more than 15 migraine days a month. Migraine can be extremely disabling and costly, accounting for more than $20 billion in direct and indirect expenses each year in the United States.
The Best Places Organization ranks U.S. cities by migraine prevalence according to several factors, including the number of migraine-related drug prescriptions per capita, lifestyle and environmental factors, and the consumption of migraine-triggering foods. The Cincinnati Metropolitan Area, which includes large parts of Northern Kentucky, ranks first, and both Louisville and Lexington are in the top 30.
"Our hope is that KNI will be a Phase III test site," Kapoor said. "We have notable expertise in migraine treatment, and we are located at the epicenter of migraine incidence."
LEXINGTON, Ky. (June 22, 2015) — In a corner of Larry Goldstein's office on the fourth floor of the Kentucky Clinic sits a Captain's chair — a common sight in faculty offices everywhere. But a closer inspection of the emblem on the chair reveals the "Eruditio et Religio" motto of Duke University.
You don't see that often at the University of Kentucky.
"As the (NCAA men's basketball) tournament progressed, I was more and more fatalistic," said Goldstein, who accepted the chairmanship of the UK Department of Neurology in January. "I knew that if UK and Duke played in the final, either way, I couldn't win. The University of Western Siberia was starting to look like a better career option."
But as soon as the conversation veers away from the storied Duke-UK rivalry, he gets serious.
A highly acclaimed expert in stroke and other related neurological disorders, Goldstein comes to UK with a resolve to apply his skills and experience to propel the department — and its sister, the Kentucky Neuroscience Institute — to the next level of research, patient care, education and service.
"There is so much talent here (at UK ) already, and so much to offer Kentuckians in terms of specialty neurology care," Goldstein said. "I hope to organize our resources in a way that maximizes the efficiency of clinical care, clinical research, and translational/biomedical collaborations at the same time we provide service and leadership for the citizens of the commonwealth."
Goldstein received his undergraduate degree from Brandeis University in 1977 and his MD from Mount Sinai School of Medicine in 1981. He then completed his internship and neurology residency at Mount Sinai before venturing to Duke University in 1985 for a research fellowship, where rose through the ranks to become a professor of neurology, chief of the Division of Stroke and Vascular Neurology, director of the Duke Stroke Center and an attending neurologist at the Durham VA Medical Center until his arrival here last month.
Most people are drawn to Kentucky for its unique landscape. Goldstein came to Lexington in part because of something less appealing.
"Kentuckians suffer from strokes at a higher rate than almost anywhere else in the U.S.," Goldstein said. "Since medical school, I've had a focused interest in stroke prevention, acute intervention, post stroke recovery, and systems of care."
"This seemed to be the perfect place at the right time to apply my research focus and career interests." “When I combined this with the opportunity to work with outstanding colleagues at UK to develop programs that will make a real difference in people’s lives, I was convinced there was no better place in the country for me to work.”
Goldstein has published more than 650 peer-reviewed journal articles, editorials, book chapters, abstracts, and other professional papers. He indicated that, “the faculty at Academic Medical Centers are in a unique position to influence public policy for the benefit of the patients we serve.” As a member of the American Heart Association National Spokesperson panel and past national chairman of the AHA Advocacy Committee he is a noted voice in educating the public, medical professionals and policymakers about stroke and cardiovascular disease. By helping to promote the AHA’s adoption of stroke as one of its primary missions, Goldstein assisted with the AHA's initiation of the development of stroke centers and the Get with the Guidelines-Stroke program. He has also supported the specialty of neurology nationally through work on several committees of the American Academy of Neurology.
Goldstein has won numerous awards, including the AHA’s Chairman’s Award, its National Volunteer Advocate of the year, the Stroke Council Leadership Award and the Feinberg Award for excellence in stroke. He has been awarded more than 15 million dollars in grant support throughout his career studying cerebrovascular disease, pharmacological approaches to recovery after stroke, motor recovery, and mechanisms of behavioral recovery after focal brain injury.
His clinical and research interests are complemented by his commitment to educating the next generation of neurologists, and he is particularly proud of his several teaching awards. To that end, Goldstein hopes to enhance programs at UK that foster faculty career development and enhance the Department’s educational programs.
“Dr. Goldstein brings to the university a great balance of clinical experience and research expertise,” said Dr. Frederick C. de Beer, dean of the UK College of Medicine. "His interest and skill in the area of stroke is particularly relevant to our patient population, since cardiovascular events, including stroke, occur at such high rates."
“I am thrilled to be at UK and to have been given the opportunity to work with outstanding colleagues to continue to help build what I am convinced will be one of the best neuroscience programs in the country,” Goldstein said.
LEXINGTON, Ky. (June 19, 2015) — The University of Kentucky's Health Care Committee of the UK Board of Trustees were presented a strategic plan that will guide UK HealthCare through 2020. The committee met Thursday during their annual retreat.
Building upon the success of the past 10 years, the plan continues to emphasize caring for the most complex, critically ill patients in Kentucky and beyond.
Some of the statistics and figures presented that reflect UK HealthCare's growth include:
In approving the new strategic plan, UK HealthCare officials asked for a commitment from its leaders, stakeholders and partners to move forward and achieve its vision by giving latitude for collaborative models, committing to clinical excellence and providing an outstanding patient experience as well as service line integration. From its statewide partners, it was asked for participation in a statewide collaborative that fosters success against the challenges of the future.
"The 2020 Strategy is built on a foundation of patient-centered care and a patient-centered culture that includes growth in complex care as well as ambulatory care; strengthening partnership networks to reduce costs, and increase efficiency; and value-based care and payments which improve predictability of outcomes and cost while adopting evidence-based leading practices," said UK Vice President for Health Affairs Dr. Michael Karpf.
The plan includes developing a cultural change program in order to support the 2020 strategic vision. The program will identify key cultural strengths and opportunities. The goal will be to design a patient-centric experience that positions UK HealthCare to be Kentucky's destination provider for complex care and it will enable staff and leadership to be ambassadors of the patient-centered culture and UK HealthCare brand.
Also detailed in the Strategic Plan is growth in complex care and in ambulatory (outpatient care). As part of this goal, substantial service line growth is needed in the next five years. Additionally, ambulatory specialty care will also need to grow by improving access to UK HealthCare specialists and developing a patient-centered care model as well as partnering with community physicians.
As part of the service line growth, the focus will continue to be on treating the most complex patients and partnering with community providers to keep lower acuity patients in their home community.
Service line areas of primary focus for growth will be the Gill Heart Institute, Kentucky Children's Hospital, Markey Cancer Center, Kentucky Neuroscience Institute, High-Risk Obstetrics and Neonatal Intensive Care, Solid Organ Transplantation, Digestive Health, Musculoskeletal, and Trauma and Acute Care Surgery.
Clinical and support services that UK HealthCare will invest in to enable growth in these service lines includes excellence in quality and operational efficiency; redesigning the transfer management processes in order to create capacity and treat patients in the appropriate care setting and return them to our community partners; and develop a service line operating model to support and coordinate comprehensive, multidisciplinary care across the continuum and community.
These same strategies will be used to expand ambulatory specialty care.
To achieve this plan, a new service line operating model will be implemented to enable and enhance the organization's strategic initiatives. This new model will incorporate the transition from department and specialty driven care to multidisciplinary, multi-specialty care; episodic and high-acuity focused care to disease and cross continuum focused care; from provider centric to patient centric; from individual physician or specialty care to team care delivery involving multiple specialties; and UK HealthCare management of high-acuity care to collaboration with external partners to optimize site and level of care.
Integrated technology that standardizes data across the organization and enables population health management will be utilized.
Another overarching premise of the 2020 Strategic plan is the strengthening of partnership networks including acute care partnerships, post-acute care partnerships, primary care and community care. As part of future planning, UK will develop a primary care network to ensure a seamless experience across the care continuum and position the organization for value-based care and population health.
The third selected strategy in the plan is value-based care. In order to provide enhanced value for patients, UK HealthCare will develop a "best in class" quality management program.
This strategy includes improving the predictability of outcomes, cost of care, and adoption of evidence-based practices throughout the enterprise across all settings of care.
"To be successful, patient care in the future must be affordable, accessible, coordinated, efficient and high quality with a shift to improving health outcomes and rationalizing but not rationing care," said Karpf.
He added that although a significant amount of time and effort has been invested in developing this strategic plan, UK HealthCare’s strategic journey does not end here.
"We will continue with work in the weeks and months to come to set priorities, develop timelines, and track progress and results."
Media Contact: Kristi Lopez, 859-323-6363, Kristi.firstname.lastname@example.org
LEXINGTON, Ky. (June 9, 2015) – The University of Kentucky's Kentucky Neuroscience Institute, Office of Clinical Simulation and the UK HealthCare/Norton Healthcare Stroke Care Network have joined forces to offer a new kind of symposium for neuroscience and stroke care.
The Clinical & Translational Neuroscience Exposition on June 26 will be an informative, interactive event exploring the latest advancements in the neurosciences and stroke care. The Expo replaces the Clinical Neuroscience Winter Expo, which was cancelled in March due to weather.
"We wanted this to be very different from traditional symposia, so the Expo is designed to be highly interactive," Dr. Michael Dobbs, interim chair for the University of Kentucky's Department of Neurology and director of UK HealthCare's Stroke Network, said. "Through the use of interactive learning methods and patient simulation equipment, our goal is to help attendees learn by doing and translate this new-found experience to current treatment practices."
Speakers from multiple specialties have been chosen to be able to cover a broad range of neuroscience topics in this one-day event.
The keynote speaker will be Dr. Avindra Nath, clinical director of NINDS, the director of the Translational Neuroscience Center and the chief of the Section of Infections of the Nervous Systems at the National Institutes of Health in Washington, who will present "Cracking the Code of Neuroinflammatory Disorders."
Pointing to the fact that the human and economic impact of neurological disorders is exacerbated by a prevailing shortage of neuroscience specialists and the burgeoning aging population, Dobbs emphasized augmenting multi-specialty provider groups’ neuroscience awareness and knowledge base is key to improving equitable access and patient outcomes.
"Our goal with this event is to provide that guidance in a new and interesting way, to the ultimate benefit of patients."
Attendees can register online or in person the day of the event at 7:00 a.m. in Pavilion A of the Albert B. Chandler Medical Center.
Registration fees range from $12-$50, a reduction from the registration fees for the Winter Expo. Anyone who registered for the Winter Expo qualifies for a full refund and can re-register online or in person.
For more information about the Expo or to register, go to: http://www.cecentral.com/live/10269
LEXINGTON, Ky. (May 19, 2015) -- Thirteen-year-old Abby Gottesman watched through the glass as the pineapple was strapped into place and made its way through the center of an enormous donut.
It sounds like something from the school cafeteria, but in fact Abby was enjoying her dream day learning from neuropsychologists from UK HealthCare.
Most 13-year-olds aren't really certain what they want to be when they grow up, or their career aspirations are more generic: nurse, fireman, lawyer. But Abby's career goal to be a neuropsychologist puts her in rarefied company. Her essay outlining her life's pursuit and why she felt she would be a good neuropsychologist made her one of only five middle schoolers in the country chosen to shadow people in their chosen discipline through the DreamUP! Program.
The DreamUP! Program is a no-cost career exploration program and contest for middle school students across the United States sponsored by Office Depot and USA TODAY. The program is designed for students to follow a set of career exploration lessons and concludes with students writing a 500-word essay about their dream job/career.
"When I read Abby's essay entry I was blown away," said Amelia Anderson-Mooney, Ph.D., the neuropsychologist who planned Abby's dream day. "This young woman will achieve anything she puts her mind to."
Neuropsychologists specialize in assessing the cognitive and behavioral effects of neurological disorders such as Parkinson's disease, Down syndrome, and Alzheimer's disease. By using standardized testing to assess behavior and cognition, coupled with technology such as MRI, neuropsychologists aim to understand how brain function influences the cognitive and behavioral symptoms of neurological disease. They work hand-in-hand with neurologists and other physicians to assist patients in managing their situation safely and effectively.
Anderson-Mooney wanted to make sure that Abby learned about essential brain functions and the tools neuropsychologists use to measure those functions. So the seventh grader from Lexington Traditional Magnet School started her day with the Neurocognitive Service team at UK HealthCare's Kentucky Neuroscience Institute, learning about their educational backgrounds and gaining hands-on experience with the cognitive tests neuropsychologists use with their patients.
The group then discussed a case study so that Abby could to see how those tests are used in real life The day concluded with a visit to UK's Magnetic Resonance Imaging/Spectroscopy Center (MRISC), where they put a pineapple through an MRI to demonstrate how the technology helps assess brain structure. Finally, with the MRISC’s Dave Powell, Ph.D. at the controls, Anderson-Mooney served as a human volunteer for fMRI (functional magnetic resonance imaging), which demonstrates in real time which parts of the brain are responsible for motor control as Anderson-Mooney followed simple instructions presented to her on a screen.
"I was extremely excited because this is a big deal," said Abby. "It's great exposure so I can know what I'm going to do when I grow up."
And Abby wasn't the only one who enjoyed the experience.
"It’s my opinion that I have the best job in the world with the best people in the world, and I was very proud to introduce Abby to it,” Anderson-Mooney said.
LEXINGTON, Ky. (April 22, 2015) -- To date, a cure for Parkinson's disease (PD) remains elusive for the more than 50,000 Americans diagnosed yearly, despite decades of intensive study. But a newly approved treatment that might help ease the symptoms of Parkinson's has shown remarkable promise.
Dr. John Slevin, professor of neurology at the University of Kentucky College of Medicine and vice chair of research at the Kentucky Neuroscience Institute, worked with a team of international investigators to explore the efficacy of continuous levodopa dosing using a specially developed gel called CLES (Duopa) that is delivered directly into the small intestine by a portable infusion pump.
"We were extremely pleased with the results," Slevin said. “Patients with advanced PD treated via this new method demonstrated marked improvement in symptom fluctuations with reduced dyskinesia.“
According to Slevin, CLES's effectiveness is due in part to the fact that it results in more stable plasma concentrations of levodopa by delivering it directly to the small intestine, which bypasses issues of erratic gastric emptying and absorption caused by reduced muscular function inherent to PD.
"CLES has the potential to address a significant unmet need in this patient population with limited therapeutic options," Slevin added.
Marion Cox knows this all too well. This 70-year old Georgetown farmer and former real estate developer has suffered from Parkinson's for 16 years.
"I could tell I was going the wrong way," Cox says as he described his decline in spite of frequent medication adjustments. Even with his medications, he began to "stagger around" and struggled to speak and swallow. He was frustrated that he couldn't spend more quality time with his two daughters and two granddaughters. So when Dr. Slevin mentioned the Duopa clinical trial, Marion leapt at the chance.
"I felt different right away," he says of his experience in the three-year clinical drug trial. Cox shares that he can get around better, get dressed more easily, be gone all day farming his 800 acres.
"I'm getting more done. I'm not as good as I once was (before I had Parkinson's) but I'm pretty darn well off," he adds.
Parkinson’s is a progressive disease caused by the death of dopamine-producing cells in the brain. While most people recognize a Parkinson's patient by their motor skill difficulties such as tremor, slowness and stiffness, the disease also gives rise to several non-motor types of symptoms such as sensory deficits, cognitive difficulties or sleep problems.
While doctors have a number of treatments available to help manage the symptoms of Parkinson's disease, the motor deficits that are the hallmarks of PD are also the nemesis of effective treatment, since the muscles that control digestion are also affected, making dosing -- both in terms of amount and timing -- challenging.
Compounding this challenge is the fact that medications lose effectiveness over time as cell death progresses. Although levodopa remains the “gold standard” to control motor deficits in the treatment of early stage PD, after four to six years of treatment with oral medications for Parkinson’s disease, about 40 percent of patients find those medications less effective overall, inconsistent in controlling muscle function, and accompanied by a bothersome side-effect called dyskinesia, or involuntary muscle movement. By nine years of treatment, about 90 percent will suffer these effects.
The FDA approved CLES in January 2015. Because the safety and efficacy of levodopa is already established, this treatment has the potential to be fast-tracked for widespread use within the next 4-6 months.
Results from the study were published in the current issue of the Journal of Parkinson’s Disease. The article is available at http://iospress.metapress.com/content/04427r3701341251/fulltext.pdf.
The archived press conference can be viewed at: Www.youtube.com/watch?v=kpPlrzcEyCo
LEXINGTON, Ky. (April 9, 2015) - UK HealthCare's Kentucky Neuroscience Institute (KNI) has received the "Get With The Guidelines -"Stroke Gold-Plus Quality Achievement Award" by the American Heart Association/American Stroke Association for maintaining nationally recognized standards for the treatment of stroke patients.
KNI also received the association’s Target: Stroke Honor Roll Elite for meeting stroke quality measures that reduce the time between hospital arrival and treatment with the clot-buster tPA, the only drug approved by the U.S. Food and Drug Administration to treat ischemic stroke. Over twelve months, at least 75 percent of the hospital’s ischemic stroke patients have received tPA within 60 minutes of arriving at the hospital (known as door-to-needle time). Stroke patients who receive tPA within three hours of the onset of symptoms may recover more quickly and are less likely to suffer severe disability.
This year marks the fifth year that KNI has received Gold Plus designation. KNI has been named to the Target: Stroke Honor Roll the past two years and meets the criteria for the 'elite' level that was introduced this year.
Kentucky patients aren't the only ones benefiting from this achievement.
"By participating in the Get With The Guidelines-Stroke program, we are able to share our expertise with other member hospitals around the country, including access to the most up-to-date research, clinical tools and resources, and patient education resources," said Dr. Jessica Lee, director of UK HealthCare's Comprehensive Stroke Program.
"What this means for Kentuckians is that the best possible stroke care is available right here in Lexington."
According to the American Heart Association/American Stroke Association, stroke is the number five cause of death and a leading cause of adult disability in the United States. In Kentucky, cardiovascular disease (which includes stroke) is the leading cause of death. On average, someone suffers a stroke every 40 seconds; someone dies of a stroke every four minutes; and 795,000 people suffer a new or recurrent stroke each year.
LEXINGTON, Ky. (March 30, 2015) -- Humans discovered the usefulness of lead centuries ago. Abundantly available, easily molded and extremely resistant to corrosion, lead was considered ideal for many uses, including insecticides, paint pigment, soldering for canned foods, and pipes for plumbing.
Scientists were aware that acute lead toxicity caused by high levels of lead absorption could cause significant health problems and even death, but it was not until the 1970s that it became clear that chronic exposure to low levels of lead could also have significant long term health effects, particularly cognitive and behavioral impairment. Children are particularly vulnerable because of their developing nervous systems.
Aggressive steps were taken to reduce the amount of lead in the environment. Lead based paint was banned in 1978, lead pipes for plumbing have been restricted since 1988, and lead based gasoline was phased out and ultimately banned in 1995. Water supplies are subject to strict regulation and lead levels are monitored closely in schools and daycares. Occupational exposure is also closely monitored. These measures have been highly successful: mean blood lead levels have decreased almost 80 percent from 1976 to 1991.
Today, other than occupational exposure, the most common sources of lead are found in the paint and pipes of old buildings, and in glazed pottery, some makeup, and folk medicine, especially from other countries.
It is recommended that children be screened for lead by age 2, particularly if they live in a building that was built before 1978. This way, intervention can be taken before long term problems occur. Ask your doctor to screen your child for lead exposure.
Watch out for lead in your home, particularly if your house is older. When old paint cracks and peels, it creates dangerous, almost invisible dust particles that you absorb just by breathing. Watch your children, especially babies (who like to put things in their mouths), who might try to eat paint chips. Home repairs like sanding or scraping paint can also create dangerous lead dust. You should not be in the house while someone is cleaning up after renovations, painting, or remodeling a room with lead paint.
Talk to your doctor about any medicines or vitamins you take. Some folk medicines and dietary supplements may have lead in them. Use caution when eating candies, spices, and other foods from foreign countries, especially if they appear to be noncommercial products.
Avoid using imported lead-glazed ceramic pottery produced in cottage industries, leaded crystal, and/or pewter or brass containers or utensils to cook, serve or store food. Do not use dishes that are chipped or cracked.
Overall, the rapid decrease of lead exposure in the environment in this country has been the remarkable result of a thorough public health campaign. Let’s continue to be diligent and ensure that everyone, especially children, is protected from the effects of lead toxicity.
Dr. Kimberly S. Jones is a neurologist at UK HealthCare’s Kentucky Neuroscience Institute
This column appeared in the March 29, 2015 edition of the Lexington Herald-Leader
ALS (Lou Gehrig's disease)
Cerebrovascular disorders (stroke)
Comprehensive epilepsy program
Headache & pain clinic
Memory and aging program
Kentucky Clinic | Directions »First floor, Wing C (across from Starbucks)740 S. Limestone Lexington KY 40536
UK Albert B. Chandler Hospital | Directions »
UK Good Samaritan Hospital | Directions »
Morris K. Udall Centers of Excellence »
Sanders-Brown Center on Aging »
VA Medical Center »
Monday - Friday8 a.m. - 5 p.m.
Request an appointment online »
Most commonly, patients are referred through their primary care provider or neurologist.
Please arrive at least 20 minutes before your appointment in order to register and fill out any of the necessary paperwork prior to your appointment. This will assist in ensuring prompt service and visitation with your physician.
When a patient is referred to Kentucky Neuroscience Institute (KNI), diagnosis and treatment are made in a collaborative environment, decreasing the need for multiple visits and consultations.
An emphasis on quality of life factors such as ease of movement and communication maximizes the potential for recovery. Treated as equal partners in care, referring physicians can expect early and ongoing contact with KNI specialists.
Kentucky Neuroscience Institute ClinicKentucky Clinic Directions | Parking »First floor, Wing C (across from Starbucks) 740 S. Limestone Lexington KY 40536-0284